Successes and challenges in the development of BD1-selective BET inhibitors: a patent review.

Monica VivianoAlessandra CiprianoEmanuele FabbriziAlessandra FeoliSabrina CastellanoGianluca SbardellaAntonello MaiCiro MiliteDante Rotili

Published in: Expert opinion on therapeutic patents (2024)

The development of BD1-selective BETi, despite challenging, is highly desirable as it could have a great impact on the development of new safer anticancer therapeutics. Several strategies could be applied to discover potent and selective compounds with limited side effects.

Keyphrases

small molecule
anti inflammatory